
Biotech 2050 Podcast
Adapting Through Disruption in Biotech, David Esposito, President & CEO, ONL Therapeutics
Jan 10, 2024
CEO of ONL Therapeutics, David Esposito, discusses challenges and opportunities in ophthalmology, including the impact of the Inflation Reduction Act (IRA) on indication selection and the evolving capital market for biotech companies. They also talk about proving safety and tolerability in new mechanisms of action, shifting towards chronic indications, and the relationship between big pharma and early-stage biotechs. Essential listening for ophthalmology professionals seeking to navigate industry challenges and understand the IRA's implications.
25:30
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The Inflation Reduction Act (IRA) has had a significant impact on indication selection and the evolving capital market for biotech companies in the ophthalmology field.
- The COVID-19 pandemic posed challenges to running preclinical and clinical programs in ophthalmology, requiring companies to adapt strategies and improve efficiencies.
Deep dives
David Esposito's Career Journey and Leadership Reflections
David Esposito, CEO of O&L Therapeutics, shares his career journey, starting with his early years in the military and then transitioning into big pharma. He later ventured into the early and mid-stage life sciences sector, leading successful companies and learning from challenges. He reflects on how his military experience shaped his leadership style, emphasizing the importance of leading by example and adaptability. As a CEO, he has evolved to take personal ownership and accountability for both his impact and the scaling of the organization. His principles remain consistent, but their applications have adjusted for the unique demands of early-stage companies.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.